At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Lenalidomide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia
In Brief
A Phase 2 clinical trial evaluating Lenalidomide and Azacitidine for Leukemia, Myeloid, Acute. Completed, enrolled 31 participants across 1 site.
Detailed Summary
Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartApr 2010
Primary CompletionNov 2013
Study CompletionOct 2014
TodayJul 2026
First PostedNov 19, 2009
Enrollment StartApr 1, 2010
Primary CompletionNov 1, 2013
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 16.6 years ago
Interventions
Lenalidomidedrug
Azacitidinedrug